Clinical Trial

Observational Study on Determinants of Dementia After Stroke

Study acronym: DEDEMAS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The primary aim of the DEDEMAS (Determinants of Dementia After Stroke) study is to identify predictors of post stroke dementia (PSD). A particular focus will be on biological markers (neuroimaging, biochemical markers derived from blood) and on interactions between vascular and neurodegenerative mechanisms. For this purpose patients with an acute stroke and without prior dementia will be followed for 10 years. Note: Starting from 01.01.2014 this study is expanded to a multi-centric design funded by the German Center for Neurodegenerative Diseases (The DZNE - Mechanisms of Dementia After Stroke (DEMDAS) Study). This includes the following study sites: DZNE/München - Institute for Stroke and Dementia Research, Klinikum der Universität München (Coordinator); DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité; DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn; DZNE/Göttingen - University Medical Center Göttingen; DZNE/Magdeburg - Universitätsklinikum Magdeburg.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2011-04-12; most recent amendment 2024-03-18.
Status change: Recruiting → Active, Not Recruiting 2019-08-13
Status change: Not Yet Recruiting → Recruiting 2011-04-29
Trial Details
NCT Number NCT01334749
Lead Sponsor Ludwig-Maximilians - University of Munich
Conditions Ischemic Stroke, Hemorrhagic Stroke
Enrollment 736 participants
Start Date 2011-04
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-20